Using MRI to investigate simvastatin in secondary progressive MS

Neurologist examining an MRI scan

Dr Jeremy Chataway

UCL Institute of Neurology

£309, 345
 

About the project

Simvastatin is being tested as a potential treatment for secondary progressive MS. The drug showed promise in earlier clinical trials, reducing the rate of brain shrinkage by 43%, compared with placebo. This research is now being taken forward into a larger phase 3 trial, MS-STAT2, which began in 2017.

In a sub-study of MS-STAT2, the team want to use MRI to try and find ways to improve the efficiency of clinical trials, and to help us understand more about the biology of progressive MS.

Our researchers will recruit 240 people, who are also taking part in MS-STAT2. The volunteers will have MRI scans at the beginning of the study, with additional scans after one, two and three years.

These scans will be analysed to confirm whether brain shrinkage is an effective way of measuring if a drug is working in progressive MS. The team will also look at other MRI findings to see if any can give us a quicker idea of whether a clinical trial has been successful or not.

Finally, it’s hoped the MRI findings will help us to understand more about how simvastatin works in secondary progressive MS.
 

How will it help people with MS?

If successful, this project could help us to determine the best way to test the benefits of drugs in progressive MS trials.

The research will also help us to understand how simvastatin works, as well as giving us a great insight into the biology of secondary progressive MS. This could open the door to new treatment avenues.
 

The difference you can make

The race is on to find therapies that will slow progression. You can help speed up the process by supporting projects like this.

>> Donate now to fund MS research

What's new?